UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

International Myeloma Working Group molecular classification of multiple myeloma: spotlight review

Leukemia, 2009-12, Vol.23 (12), p.2210-2221

2009

Volltextzugriff (PDF)

Single-cell analysis of targeted transcriptome predicts drug sensitivity of single cells within human myeloma tumors

Leukemia, 2016-05, Vol.30 (5), p.1094-1102

2016

Volltextzugriff (PDF)

Clinical and biological significance of RAS mutations in multiple myeloma

Leukemia, 2008-12, Vol.22 (12), p.2280-2284

2008

Volltextzugriff (PDF)

Reduced CXCR4 expression is associated with extramedullary disease in a mouse model of myeloma and predicts poor survival in multiple myeloma patients treated with bortezomib

Leukemia, 2013-10, Vol.27 (10), p.2075-2077

2013

Volltextzugriff (PDF)

Clinical significance of TP53 mutation in myeloma

Leukemia, 2007-03, Vol.21 (3), p.582-584

2007

Volltextzugriff (PDF)

A gene expression signature distinguishes innate response and resistance to proteasome inhibitors in multiple myeloma

Blood cancer journal (New York), 2017-06, Vol.7 (6), p.e581-e581

2017

Volltextzugriff (PDF)

High-throughput drug screening identifies compounds and molecular strategies for targeting proteasome inhibitor-resistant multiple myeloma

Leukemia, 2014-11, Vol.28 (11), p.2263-2267

2014

Volltextzugriff (PDF)

Deletions of chromosome 13 in multiple myeloma identified by interphase FISH usually denote large deletions of the q arm or monosomy

Leukemia, 2001-06, Vol.15 (6), p.981-986

2001

Volltextzugriff (PDF)

Distinct IL-6 signal transduction leads to growth arrest and death in B cells or growth promotion and cell survival in myeloma cells

Leukemia, 2002-06, Vol.16 (6), p.1182-1188

2002

Volltextzugriff (PDF)

Genetic polymorphisms of EPHX1, Gsk3β, TNFSF8 and myeloma cell DKK-1 expression linked to bone disease in myeloma

Leukemia, 2009-10, Vol.23 (10), p.1913-1919

2009

Volltextzugriff (PDF)

The bone marrow stromal microenvironment influences myeloma therapeutic response in vitro

Leukemia, 2001-02, Vol.15 (2), p.264-271

2001

Volltextzugriff (PDF)

The structure of ownership and corporate acquisition strategies

Strategic management journal, 2002-01, Vol.23 (1), p.41-53

2002

Volltextzugriff (PDF)

Interferon-α protects myeloma cell lines from dexamethasone-induced apoptosis

Leukemia, 1999-03, Vol.13 (3), p.473-480

1999

Volltextzugriff (PDF)

Sequential analysis of bone marrow and peripheral blood after stem cell transplant for myeloma shows disparate tumor involvement

Leukemia, 1997-09, Vol.11 (9), p.1565-1570

1997

Volltextzugriff (PDF)

Is Flow Cytometric DNA Content Hypodiploidy Prognostic in Multiple Myeloma?

Leukemia & lymphoma, 1999, Vol.35 (1-2), p.83-89

1999

Volltextzugriff (PDF)

Glucose-dependent regulation of glucose transport activity, protein, and mRNA in primary cultures of rat brain glial cells

The Journal of biological chemistry, 1988-10, Vol.263 (30), p.15594-15601

1988

Volltextzugriff (PDF)

Do investors prefer even-eighth prices? Evidence from NYSE limit orders

Journal of banking & finance, 2003-04, Vol.27 (4), p.719-748

2003

Volltextzugriff (PDF)

Managing incidental findings and research results in genomic research involving biobanks and archived data sets

Genetics in medicine, 2012-04, Vol.14 (4), p.361-384

2012

Volltextzugriff (PDF)

Heterogeneity in therapeutic response of genetically altered myeloma cell lines to interleukin 6, dexamethasone, doxorubicin, and melphalan

Blood, 2000-11, Vol.96 (9), p.3175-3180

2000

Volltextzugriff (PDF)

Prognostic significance of the S‐phase fraction of light‐chain‐restricted cytoplasmic immunoglobulin (cIg) positive plasma cells in patients with newly diagnosed multiple myeloma enrolled on eastern cooperative oncology group treatment trial E9486

American journal of hematology, 1999-08, Vol.61 (4), p.232-237

1999

Volltextzugriff (PDF)

Activating mutations of N- and K-ras in multiple myeloma show different clinical associations : Analysis of the Eastern cooperative oncology group phase III trial

Blood, 1996-10, Vol.88 (7), p.2699-2706

1996

Volltextzugriff (PDF)

Initiation and processing of two kappa immunoglobulin germ line transcripts in mouse B cells

Molecular and Cellular Biology, 1990-05, Vol.10 (5), p.1950-1958

1990

Volltextzugriff (PDF)

The polycomb group protein enhancer of zeste homolog 2 (EZH2) is an oncogene that influences myeloma cell growth and the mutant ras phenotype

Oncogene, 2005-09, Vol.24 (41), p.6269-6280

2005

Volltextzugriff (PDF)

Clinical significance of TP53 mutation in myeloma

Leukemia, 2007-03, Vol.21 (3), p.582-584

2007

Volltextzugriff (PDF)

Clinical and biologic implications of recurrent genomic aberrations in myeloma

Blood, 2003-06, Vol.101 (11), p.4569-4575

2003

Volltextzugriff (PDF)

1 – 25 von 331

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(303)
Mit Volltextzugriff
(281)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Englisch
(330)
Deutsch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(210)
Life Sciences & Biomedicine
(192)
Humans
(160)
Biological And Medical Sciences
(107)
Female
(83)
Medical Sciences
(83)
Oncology
(62)
Male
(55)
Middle Aged
(51)
Animals
(50)
Hematology
(50)
Aged
(47)
Adult
(45)
Mice
(38)
Multiple Myeloma
(36)
Risk Factors
(32)
Base Sequence
(31)
Fundamental And Applied Biological Sciences. Psychology
(30)
Immunoglobulin Kappa-Chains - Genetics
(30)
Immunodeficiencies. Immunoglobulinopathies
(27)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

International Myeloma Working Group molecular classification of multiple myeloma: spotlight review

Single-cell analysis of targeted transcriptome predicts drug sensitivity of single cells within human myeloma tumors

Clinical and biological significance of RAS mutations in multiple myeloma

Reduced CXCR4 expression is associated with extramedullary disease in a mouse model of myeloma and predicts poor survival in multiple myeloma patients treated with bortezomib

Clinical significance of TP53 mutation in myeloma

A gene expression signature distinguishes innate response and resistance to proteasome inhibitors in multiple myeloma

High-throughput drug screening identifies compounds and molecular strategies for targeting proteasome inhibitor-resistant multiple myeloma

Deletions of chromosome 13 in multiple myeloma identified by interphase FISH usually denote large deletions of the q arm or monosomy

Distinct IL-6 signal transduction leads to growth arrest and death in B cells or growth promotion and cell survival in myeloma cells

Genetic polymorphisms of EPHX1, Gsk3β, TNFSF8 and myeloma cell DKK-1 expression linked to bone disease in myeloma

The bone marrow stromal microenvironment influences myeloma therapeutic response in vitro

The structure of ownership and corporate acquisition strategies

Interferon-α protects myeloma cell lines from dexamethasone-induced apoptosis

Sequential analysis of bone marrow and peripheral blood after stem cell transplant for myeloma shows disparate tumor involvement

Is Flow Cytometric DNA Content Hypodiploidy Prognostic in Multiple Myeloma?

Glucose-dependent regulation of glucose transport activity, protein, and mRNA in primary cultures of rat brain glial cells

Do investors prefer even-eighth prices? Evidence from NYSE limit orders

Managing incidental findings and research results in genomic research involving biobanks and archived data sets

Heterogeneity in therapeutic response of genetically altered myeloma cell lines to interleukin 6, dexamethasone, doxorubicin, and melphalan

Prognostic significance of the S‐phase fraction of light‐chain‐restricted cytoplasmic immunoglobulin (cIg) positive plasma cells in patients with newly diagnosed multiple myeloma enrolled on eastern cooperative oncology group treatment trial E9486

Activating mutations of N- and K-ras in multiple myeloma show different clinical associations : Analysis of the Eastern cooperative oncology group phase III trial

Initiation and processing of two kappa immunoglobulin germ line transcripts in mouse B cells

The polycomb group protein enhancer of zeste homolog 2 (EZH2) is an oncogene that influences myeloma cell growth and the mutant ras phenotype

Clinical significance of TP53 mutation in myeloma

Clinical and biologic implications of recurrent genomic aberrations in myeloma

Suchergebnisse filtern